Project Grant R41DA047186

Syncanica Bio, Inc. received a Project Grant of $334,343 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded June 15, 2025, with completion targeted for May 31, 2027. The company is developing fully synthetic analogs of 8,9-dihydrocannabidiol (H2CBD) as therapeutic agents to treat substance use disorder (SUD), a public health crisis with limited treatment options. This research builds on preliminary evidence indicating that...

Federal Cooperative Agreement Award Summary Sparian Biosciences Inc. (doing business as Palion Therapeutics) received a $6.28 million cooperative agreement award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to support the clinical development of SBS-147, a first-in-class oral arylepoxamide agonist non-opioid pain treatment. The award, obligated on July 1, 2025, with a completion date of June 30, 2027, funds research and...

Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Washington University $1,320,580 under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on the analgesic potential of novel peripherally-restricted cannabinoid type 1 receptor (CB1R) ligands. The award, effective August 1, 2025, through April 30, 2030, funds preclinical research designed to bridge the gap between promising laboratory findings and inconsistent clinical...

This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...

Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The University of Kentucky Research Foundation a $647,142 Project Grant on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct controlled research examining the impact of cannabis on opioid self-administration in individuals with opioid use disorder. The research will be completed by November 30, 2030, and will deliver fundamental public health data addressing a critical gap...

This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $640,000 to Olfa Thera, Inc. to develop new therapeutics targeting the OLFR78/OR51E2 receptor pathway in the carotid body. The goal is to identify OLFR78/OR51E2 agonists that can strongly stimulate carotid body activity and ventilation to reverse opioid-induced respiratory depression, without the side effects of existing...

Summary of Federal Cooperative Agreement Award Akyso Therapeutics, LLC (doing business as The Drug Delivery Co LLC) received a $2.93 million Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop an extended-release buprenorphine implant for treating opioid use disorder (OUD). The award, effective August 1, 2025, through July 31, 2027, supports the development of a bioabsorbable, subcutaneous implant...

Federal Grant Award Summary The National Institute on Drug Abuse awarded a Project Grant of $182,697 (effective May 1, 2025, through August 30, 2026) to the University of Texas Health Science Center at San Antonio under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research evaluating cannabidiol (CBD) as an adjuvant therapeutic agent for opioid use disorder (OUD) treatment. The research addresses a critical public health challenge, as approximately half of OUD patients...

Federal Cooperative Agreement Summary Award: Dimerx, Inc. received a $1.59M Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective July 1, 2025, through June 30, 2027. The project aims to conduct rigorous clinical evaluation of DMX-101, a novel non-addictive analgesic that selectively targets peripheral opioid receptors while avoiding central nervous system (CNS) engagement. This two-year UG3/UH3...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $387,000.00 to Florida Atlantic University to develop novel intranasal delivery cyclic peptide analgesics for pain management. The research aims to create new peptide-based pain medications that combine kappa-opioid receptor agonist activity with serotonin and/or norepinephrine delivery, with the goal of improving pain relief while minimizing...